Table 2.
Peptide | Individual Patient OD Values to Immunogenic Vaccine Constructs |
||||||
---|---|---|---|---|---|---|---|
A | B | C | D | E | F | Dose Level | |
316-339 | 0.934 | 0.778 | 0.544 | 0.611 | 0.537 | 1.242 | 1 |
628-647 | 1.098 | 0.701 | 0.409 | 0.396 | 0.311 | 1.985 | 1 |
316-339 | 1.899 | 0.915 | 0.602 | 0.739 | 0.400 | 0.505 | 2 |
628-647 | 2.443 | 0.829 | 1.719 | 1.265 | 0.201 | 0.568 | 2 |
316-339 | 0.351 | 0.268 | 1.246 | 0.739 | 1.382 | 0.505 | 3 |
628-647 | 0.421 | 0.842 | 0.837 | 1.265 | 1.394 | 0.568 | 3 |
316-339 | 1.207 | 0.753 | 0.675 | 1.323 | 2.369 | 0.934 | 4 |
628-647 | 1.265 | 0.698 | 0.469 | 1.740 | 2.590 | 1.098 | 4 |
NOTE. Individual patients A through F are in cohorts 1 through 4. The maximum absorbance value for each patient's serum at a 1:16 dilution after subtracting preserum value was determined against MVF 316-339 and MVF 628-647. The numbers correspond to the maximum absorbance for each patient at the indicated dose level.
Abbreviations: IgG, immunoglobulin G; ELISA, enzyme-linked immunosorbent assay; OD, optical density 415 nm.